Therapeutic Antibodies: Bench to Market

Webinar Series of the Chinese Antibody Society

Upcoming Webinar

We don't have any active meetings as of now. New meetings will show up here as registration opens. Check back soon!

Recent Webinars

Sign in to view recordings

Developing human sialidase as novel cancer therapeutics for degrading sialoglycans

01/08/2023

Dr. Li Peng

Immune checkpoint blockade has revolutionized cancer treatment. However, most patients encounter resistance not yet overcome by existing therapeutic approaches, urging the need for innovative therapies. Sialoglycans have emerged as a new dimension of immune checkpoints on various tumors that impair immune response. Cleaving off sialoglycans from tumors using a tumor-associated …

Recent Advance in Neutralizing Antibody (NAb) Assay in Immunogenicity Testing for Biotherapeutics

11/19/2022

Dr. Weifeng Xu

Biotherapeutics such as mAbs are immunogenic hence can induce anti-drug Abs (ADA) including neutralizing ADA (NAb). These ADA/NAb can induce broad side-effects such as injection site overreaction, reduced exposure, to life-threatening endogenous counterpart neutralization and allergic response. Hence immunogenicity testing including ADA screening, confirmation and titer as well as NAb …

Cell Therapy is at an Inflection Point

11/17/2022

Richard Liqun Wang Ph. D., MBA.

As we moved to the 21st century, more new therapy modalities have emerged. Among them, CAR-T cell therapies have recently gained marketing approval and opened new opportunities to save lives of refractory and relapsed cancer patients. At the same time, we have to be aware of the commercial limitation on …

Inhalable fully humanized nanobodies against SARS-CoV-2

09/24/2022

Dr. Tianlei Ying

Nanobodies are typically obtained by immunizing camels or alpacas, and their animal-derived components have potential safety risks in clinical applications. In recent years, Dr. Ying’s team has developed the research and development platform for fully human nanobodies based on fully human germline genes. The team found that, due to their …

This web app is a Python Django project independently coded (frontend+backend+deployment on AWS) by Xin Yu (Github, LinkedIn) in her volunteer capacity at the Chinese Antibody Society. Contents are maintained by CAS IT team. If you're interested in participating in the future development of this web app, please submit a volunteer application and request an interview with the IT team. We require a minimum of 2 years experience as a Django developer. © Chinese Antibody Society 2021. All Rights Reserved. Legal Disclaimer
Icon